1Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量：1515
2郑筱萸主编..中药新药临床研究指导原则 试行[M].北京:中国医药科技出版社,2002:392.
3Matthews DR,Hosker JP,Rudenski AS,et al.Homestasis model assessment;insulin resistance and B-cell function from fasting plasmglucose and insulin concentration in man[J].Diabetologia,1985,28(3):412-419. 被引量：1
5Ghali P,Lindor KD.Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.Semin Liver Dis,2004,24:389-397. 被引量：1
6Harrison SA,Torgerson S,Hayashi P,et al.Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.Am J Gastroenterol,2003,98:2485-2490. 被引量：1
7Angulo P.Use of ursodeoxycholic acid in patients with liver disease.Curr Gastroenterol Rep,2002,4:37-44. 被引量：1
10Lok AS,McMahon B J; Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857-861. 被引量：1
5Caldwell SH, Hespenheide EE. Subaeute liver failure in obese women [ J ]. Am J Gastroenterol,2002,97 ( 8 ) :2058 - 2062. 被引量：1
6Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis :from cryptogenic cirrhosis to hepatocellular cancer [ J ]. Gastroenterology,2002,123 ( 1 ) : 134 - 140. 被引量：1
